Close Menu

NEW YORK — Molecular diagnostic developer Credo Biomedical is aiming to meet a growing market need for rapid point-of-care testing that combines the accuracy of PCR with the low cost of rapid immunoassays. The Singapore-based startup will launch its VitaPCR system along with a flu A/B test at the American Association for Clinical Chemistry conference in Anaheim, California next week.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.